Relative potential for selection of fluoroquinolone-resistant Streptococcus pneumoniae strains by levofloxacin: comparison with ciprofloxacin, sparfloxacin and ofloxacin - PubMed (original) (raw)
Comparative Study
. 1999 Jun:43 Suppl C:55-9.
doi: 10.1093/jac/43.suppl_3.55.
Affiliations
- PMID: 10404339
- DOI: 10.1093/jac/43.suppl_3.55
Comparative Study
Relative potential for selection of fluoroquinolone-resistant Streptococcus pneumoniae strains by levofloxacin: comparison with ciprofloxacin, sparfloxacin and ofloxacin
H B Drugeon et al. J Antimicrob Chemother. 1999 Jun.
Abstract
The aim of this study was to evaluate the relative potential of levofloxacin to select for resistance in Streptococcus pneumoniae in comparison with ciprofloxacin, sparfloxacin and ofloxacin. Two S. pneumoniae strains were studied; HBD 153 (parental strain, serotype 3) and HBD 964 (selected from the parental strain in an experimental mouse peritonitis infection model). MICs for the two strains were, respectively: 2 and 2 mg/L for ciprofloxacin; 2 and 4 mg/L for ofloxacin; 0.5 and 1 mg/L for sparfloxacin; 2 and 2 mg/L for levofloxacin. In-vitro, with 4 x MIC as the selection concentration, no mutant was obtained with strain HBD 153 (mutation frequency < 10(-8). With HBD 964, the mutation frequency was 9 x 10(-7) for ofloxacin, 10(-7) for ciprofloxacin, 4 x 10(-5) for sparfloxacin and < 10(-8) for levofloxacin. In an immunosuppressed mouse peritonitis model (20 mice per dose), the S. pneumoniae strains were studied with sc doses of ciprofloxacin, sparfloxacin and ofloxacin at 50 mg/kg od, and with sc levofloxacin at a dose of 10 and 50 mg/kg od, or 10 and 50 mg/kg bid. The MICs for strains isolated after antibiotic treatment and the mutation frequencies at 4 x MIC were determined. Against HBD 153, sparfloxacin was the most active treatment, followed by levofloxacin 10 mg/kg and 50 mg/kg bid, but strains identical to HBD 964 (showing a resistant variant at 4 x MIC) were selected by sparfloxacin. Against HBD 964, levofloxacin (10 mg/kg and 50 mg/kg) was the most active drug. Highly resistant mutants were selected by ofloxacin and ciprofloxacin, but not by sparfloxacin and levofloxacin. In conclusion, the relative potential of levofloxacin to select for fluoroquinolone-resistant S. pneumoniae is lower than that of ciprofloxacin, ofloxacin and sparfloxacin both in vitro and in vivo.
Similar articles
- In-vitro bacteriostatic activity of levofloxacin and three other fluoroquinolones against penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae.
Frémaux A, Sissia G, Geslin P. Frémaux A, et al. J Antimicrob Chemother. 1999 Jun;43 Suppl C:9-14. doi: 10.1093/jac/43.suppl_3.9. J Antimicrob Chemother. 1999. PMID: 10404331 - The susceptibility of Streptococcus pneumoniae to levofloxacin and other antibiotics.
Keller N, Smollen G, Davidson Y, Barzilai A, Keren G, Rubinstein E. Keller N, et al. J Antimicrob Chemother. 1999 Jun;43 Suppl C:1-3. doi: 10.1093/jac/43.suppl_3.1. J Antimicrob Chemother. 1999. PMID: 10404329 - Comparative antistreptococcal activity of two newer fluoroquinolones, levofloxacin and sparfloxacin.
Pfaller MA, Jones RN. Pfaller MA, et al. Diagn Microbiol Infect Dis. 1997 Nov;29(3):199-201. doi: 10.1016/s0732-8893(97)81810-x. Diagn Microbiol Infect Dis. 1997. PMID: 9401813 - Levofloxacin and sparfloxacin: new quinolone antibiotics.
Martin SJ, Meyer JM, Chuck SK, Jung R, Messick CR, Pendland SL. Martin SJ, et al. Ann Pharmacother. 1998 Mar;32(3):320-36. doi: 10.1345/aph.17178. Ann Pharmacother. 1998. PMID: 9533064 Review. - Levofloxacin, a broad spectrum anti-infective: from Streptococcus pneumoniae to Pseudomonas aeruginosa.
Schito AM, Schito GC. Schito AM, et al. J Chemother. 2004 Apr;16 Suppl 2:3-7. doi: 10.1080/1120009x.2004.11782365. J Chemother. 2004. PMID: 15255554 Review. No abstract available.
Cited by
- Evaluation of the antimicrobial, antioxidant, and anti-inflammatory activities of hydroxychavicol for its potential use as an oral care agent.
Sharma S, Khan IA, Ali I, Ali F, Kumar M, Kumar A, Johri RK, Abdullah ST, Bani S, Pandey A, Suri KA, Gupta BD, Satti NK, Dutt P, Qazi GN. Sharma S, et al. Antimicrob Agents Chemother. 2009 Jan;53(1):216-22. doi: 10.1128/AAC.00045-08. Epub 2008 Jun 23. Antimicrob Agents Chemother. 2009. PMID: 18573934 Free PMC article. - Repurposing Approved Drugs as Fluoroquinolone Potentiators to Overcome Efflux Pump Resistance in Staphylococcus aureus.
Mahey N, Tambat R, Chandal N, Verma DK, Thakur KG, Nandanwar H. Mahey N, et al. Microbiol Spectr. 2021 Dec 22;9(3):e0095121. doi: 10.1128/Spectrum.00951-21. Epub 2021 Dec 15. Microbiol Spectr. 2021. PMID: 34908453 Free PMC article. - Guide to selection of fluoroquinolones in patients with lower respiratory tract infections.
Shams WE, Evans ME. Shams WE, et al. Drugs. 2005;65(7):949-91. doi: 10.2165/00003495-200565070-00004. Drugs. 2005. PMID: 15892589 Free PMC article. Review. - Baicalin Inhibits Biofilm Formation and the Quorum-Sensing System by Regulating the MsrA Drug Efflux Pump in Staphylococcus saprophyticus.
Wang J, Jiao H, Meng J, Qiao M, Du H, He M, Ming K, Liu J, Wang D, Wu Y. Wang J, et al. Front Microbiol. 2019 Dec 10;10:2800. doi: 10.3389/fmicb.2019.02800. eCollection 2019. Front Microbiol. 2019. PMID: 31921008 Free PMC article. - Levofloxacin: an updated review of its use in the treatment of bacterial infections.
Hurst M, Lamb HM, Scott LJ, Figgitt DP. Hurst M, et al. Drugs. 2002;62(14):2127-67. doi: 10.2165/00003495-200262140-00013. Drugs. 2002. PMID: 12269858 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources